Oncology biosimilars: New developments and future directions

Biologicals have become an integral part of cancer treatment both as therapeutic agents and as supportive care agents. It is important to know that biologics are large, complex molecular entities requiring extensive immunogenicity testing and pharmacovigilance strategies to ensure no immune response...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachu, Rinda Devi, Abou‐Dahech, Mariam, Balaji, Swapnaa, Boddu, Sai H. S., Amos, Samson, Singh, Vishal, Babu, R. Jayachandra, Tiwari, Amit K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675387/
https://www.ncbi.nlm.nih.gov/pubmed/36195576
http://dx.doi.org/10.1002/cnr2.1720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675387/
https://www.ncbi.nlm.nih.gov/pubmed/36195576
http://dx.doi.org/10.1002/cnr2.1720

Ejemplares similares